AlDallal Salma M
Haematology Laboratory, Amiri Hospital, Kuwait City, Kuwait.
Ther Clin Risk Manag. 2017 Jul 20;13:905-907. doi: 10.2147/TCRM.S140023. eCollection 2017.
Ofatumumab Arzerra is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro complement-dependent cytotoxicity and antibody-dependent, cell-mediated cytotoxicity. The humanized anti-CD20 monoclonal antibody has been approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia patients. This article summarizes this antibody's therapeutic effect on chronic lymphocytic leukemia.
奥法木单抗（Arzerra）是一种人源单克隆抗体，它通过激活体外补体依赖性细胞毒性和抗体依赖性细胞介导的细胞毒性，诱导一组肿瘤B细胞系和原发性肿瘤细胞的杀伤。这种人源化抗CD20单克隆抗体已获美国食品药品监督管理局批准用于治疗慢性淋巴细胞白血病患者。本文总结了该抗体对慢性淋巴细胞白血病的治疗效果。
